Quarterly Result17 Oct 2025, 08:41 pm
RPG Life Sciences Q2 FY26: Revenue up by 7.6% Q-0-Q, EBITDA margin at 24.0%
AI Summary
RPG Life Sciences Limited has announced its financial results for the second quarter and half year ended September 30, 2025. In Q2 FY26, the company recorded a 7.6% Q-0-Q and 5.5% Y-o-Y increase in revenue, with EBITDA margins standing at a strong 24%. For H1 FY26, revenue grew by 3.8% Y-0-Y. The domestic formulations business is delivering market-beating performance with a growth of 13.5% in H1 FY26 versus Indian Pharma Market which recorded a growth of 7.4% in H1. The company remains committed to building a future-ready pharmaceutical enterprise.
Key Highlights
- Revenue from operations in Q2 FY26: Rs. 181.7 crores vs. Rs. 168.9 crores
- Y-o-Y Revenue from operations in Q2 FY26: Rs. 181.7 crores vs. Rs. 172.2 crores
- H1 FY26 Revenue from operations: Rs. 350.6 crores vs. Rs. 337.6 crores
- Domestic formulations business growth in H1 FY26: 13.5% vs. Indian Pharma Market growth of 7.4%
- EBITDA margins in Q2 FY26: 24%